Clinical events and laboratory findings in patients with HIV infection
| Case no. . | Sampling mo/y . | KS . | vIL-6 pg/mL . | hIL-6 pg/mL . | Anti-KSHV IgG OD ratio* . | CD4/CD8 cells/μL . | Antiretroviral therapy . | Anti-KS treatment . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRTI . | NNRTI . | PI . | ||||||||
| 1 | 12/87 | − | < 300 | < 1.0 | < 1.0 | 19/477 | AZT, ddC | — | — | — |
| 4/88 | + | 370 | 60.7 | < 1.0 | 2/317 | AZT | — | — | Irradiation | |
| 2 | 9/93 | + | < 300 | 3.8 | 5.92 | 242/591 | AZT | — | — | — |
| 4/99 | + | 5361 | 23.3 | 4.62 | 122/514 | ABV | NVP | IDV | ADM | |
| 6/99 | + | 7460 | < 1.0 | 4.95 | 32/255 | ABV | NVP | IDV | ADM | |
| 3 | 6/87 | + | < 300 | < 1.0 | 3.86 | 875/410 | AZT | — | — | — |
| 7/87 | + | < 300 | < 1.0 | 3.71 | 972/1458 | AZT | — | — | — | |
| 4 | 5/89 | + | < 300 | 4.6 | < 1.0 | 441/2001 | AZT | — | — | — |
| 8/89 | + | 470 | 25.0 | < 1.0 | 502/2279 | — | — | — | — | |
| 5 | 3/98 | + | 530 | 6.2 | 6.26 | 601/1328 | AZT, 3TC | — | NFV | Thalidomide |
| 4/99 | + | 714 | 3.7 | 6.61 | 714/1006 | AZT, 3TC | — | NFV | IL-12 | |
| 6/99 | + | 671 | 3.8 | 7.41 | 505/1173 | AZT, 3TC | — | NFV | IL-12 | |
| 6 | 8/98 | + | < 300 | 65.9 | 5.74 | 275/1132 | D4T, 3TC | — | IDV | — |
| 4/99 | + | < 300 | < 1.0 | 4.78 | 287/670 | D4T, 3TC | — | IDV | Thalidomide | |
| 5/99 | + | < 300 | 7.6 | 3.32 | 345/782 | D4T, 3TC | — | IDV | ADM | |
| 7 | 4/99 | + | < 300 | < 1.0 | 6.16 | 144/883 | D4T, 3TC | — | NFV | — |
| 6/99 | + | < 300 | 3.8 | 6.00 | 137/906 | D4T, 3TC | — | NFV | ADM | |
| 8 | 4/99 | + | 4507 | < 1.0 | 4.91 | 260/398 | AZT, 3TC | — | NFV | CDV |
| 6/99 | + | 4753 | < 1.0 | 4.03 | 325/340 | ABV | NVP | SQV, RTV | ADM | |
| 9 | 4/99 | − | 10 384 | < 1.0 | 5.91 | 441/2001 | F-ddA, D4T | — | NFV | — |
| 6/99 | − | 11 311 | < 1.0 | 5.69 | 502/2279 | ddI, ABV | — | SQV, RTV | — | |
| 10 | 4/99 | − | < 300 | < 1.0 | < 1.0 | 28/936 | F-ddA, D4T | — | — | — |
| 6/99 | − | < 300 | 2.4 | < 1.0 | 32/1116 | — | — | — | — | |
| Case no. . | Sampling mo/y . | KS . | vIL-6 pg/mL . | hIL-6 pg/mL . | Anti-KSHV IgG OD ratio* . | CD4/CD8 cells/μL . | Antiretroviral therapy . | Anti-KS treatment . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRTI . | NNRTI . | PI . | ||||||||
| 1 | 12/87 | − | < 300 | < 1.0 | < 1.0 | 19/477 | AZT, ddC | — | — | — |
| 4/88 | + | 370 | 60.7 | < 1.0 | 2/317 | AZT | — | — | Irradiation | |
| 2 | 9/93 | + | < 300 | 3.8 | 5.92 | 242/591 | AZT | — | — | — |
| 4/99 | + | 5361 | 23.3 | 4.62 | 122/514 | ABV | NVP | IDV | ADM | |
| 6/99 | + | 7460 | < 1.0 | 4.95 | 32/255 | ABV | NVP | IDV | ADM | |
| 3 | 6/87 | + | < 300 | < 1.0 | 3.86 | 875/410 | AZT | — | — | — |
| 7/87 | + | < 300 | < 1.0 | 3.71 | 972/1458 | AZT | — | — | — | |
| 4 | 5/89 | + | < 300 | 4.6 | < 1.0 | 441/2001 | AZT | — | — | — |
| 8/89 | + | 470 | 25.0 | < 1.0 | 502/2279 | — | — | — | — | |
| 5 | 3/98 | + | 530 | 6.2 | 6.26 | 601/1328 | AZT, 3TC | — | NFV | Thalidomide |
| 4/99 | + | 714 | 3.7 | 6.61 | 714/1006 | AZT, 3TC | — | NFV | IL-12 | |
| 6/99 | + | 671 | 3.8 | 7.41 | 505/1173 | AZT, 3TC | — | NFV | IL-12 | |
| 6 | 8/98 | + | < 300 | 65.9 | 5.74 | 275/1132 | D4T, 3TC | — | IDV | — |
| 4/99 | + | < 300 | < 1.0 | 4.78 | 287/670 | D4T, 3TC | — | IDV | Thalidomide | |
| 5/99 | + | < 300 | 7.6 | 3.32 | 345/782 | D4T, 3TC | — | IDV | ADM | |
| 7 | 4/99 | + | < 300 | < 1.0 | 6.16 | 144/883 | D4T, 3TC | — | NFV | — |
| 6/99 | + | < 300 | 3.8 | 6.00 | 137/906 | D4T, 3TC | — | NFV | ADM | |
| 8 | 4/99 | + | 4507 | < 1.0 | 4.91 | 260/398 | AZT, 3TC | — | NFV | CDV |
| 6/99 | + | 4753 | < 1.0 | 4.03 | 325/340 | ABV | NVP | SQV, RTV | ADM | |
| 9 | 4/99 | − | 10 384 | < 1.0 | 5.91 | 441/2001 | F-ddA, D4T | — | NFV | — |
| 6/99 | − | 11 311 | < 1.0 | 5.69 | 502/2279 | ddI, ABV | — | SQV, RTV | — | |
| 10 | 4/99 | − | < 300 | < 1.0 | < 1.0 | 28/936 | F-ddA, D4T | — | — | — |
| 6/99 | − | < 300 | 2.4 | < 1.0 | 32/1116 | — | — | — | — | |
OD ratios were determined by dividing the OD reading of each sample by cut-off value (average of negative control) × 3. Samples with OD ratio 1.0 were interpreted as positive.
KS indicates Kaposi sarcoma; vIL-6, viral interleukin-6; hIL-6, human IL-6; KSHV, Kaposi sarcoma–associated herpesvirus; IgG, immunoglobulin G; OD, optical density; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; PI, protease inhibitor; AZT, zidovudine; ddC, zalcitabine; ABV, abacavir; NVP, nevirapine; IDV, indinavir; ADM, liposomed adriamycin; NFV, nelfinavir; 3TC, lamivudine; D4T, stavudine; CDV, cidofovir; SQV, saquinavir; RTV, ritonavir; F-ddA, lodenosine; ddI, didanosine.